Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9908621 | 0.89 | HRH3 (0.50) | HRH3CYP1A2CYP2D6PPARGCYP3A4 | |
| SCHEMBL26329124 | 0.86 | HRH3 (0.50) | HRH3CYP1A2CYP2D6PPARGCYP3A4 | |
| SCHEMBL2614817 | 0.84 | HRH3 (0.51) | HRH3CYP1A2CYP2D6PPARGCYP3A4 | |
| SCHEMBL3864978 | 0.84 | PPARG (0.38) | HRH3CYP1A2CYP2D6PPARGCYP3A4 | |
| SCHEMBL18015059 | 0.82 | PPARG (0.57) | HRH3CYP1A2CYP2D6PPARGCYP3A4 | |
| SCHEMBL14647730 | 0.81 | HRH3 (0.47) | HRH3CYP1A2CYP2D6PPARGCYP3A4 | |
| SCHEMBL26329082 | 0.81 | HRH3 (0.49) | HRH3CYP1A2CYP2D6PPARGCYP3A4 | |
| SCHEMBL26169754 | 0.81 | HRH3 (0.42) | HRH3CYP1A2CYP2D6PPARGCYP3A4 | |
| SCHEMBL2619346 | 0.80 | HRH3 (0.59) | HRH3CYP1A2CYP2D6PPARGCYP3A4 | |
| SCHEMBL4325068 | 0.80 | PPARG (0.55) | HRH3CYP1A2CYP2D6PPARGCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767317-B1 | Methods of synthesizing enantiopure deuterium-enriched pioglitazone | POXEL SA (FR) | 2023-09-26 | — | — | US | disclosed |
| US-11319313-B2 | Crystalline forms of deuterium-enriched pioglitazone | POXEL SA (FR) | 2022-05-03 | — | — | US | disclosed |
| US-20210403464-A1 | CRYSTALLINE FORMS OF DEUTERIUM-ENRICHED PIOGLITAZONE | POXEL SA (FR) | 2021-12-30 | — | — | US | disclosed |
| US-8148541-B2 | Rhodanine derivatives, a process for the preparation thereof and pharmaceutical composition containing the same | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2012-04-03 | — | — | US | disclosed |
| US-7704996-B2 | Compounds and compositions useful as cathepsin S inhibitors | NOVARTIS AG (CH) | 2010-04-27 | — | — | US | disclosed |
| US-7704996-B2 | Compounds and compositions useful as cathepsin S inhibitors | NOVARTIS AG (CH) | 2010-04-27 | — | — | US | disclosed |
| US-20090048230-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS | NOVARTIS AG (CH) | 2009-02-19 | — | — | US | disclosed |
| US-20090048230-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS | NOVARTIS AG (CH) | 2009-02-19 | — | — | US | disclosed |
| US-20090042872-A1 | Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2009-02-12 | — | — | US | disclosed |
| US-20080194608-A1 | 6-Phenylhex-5-Enoic Acid Derivatives, Process for the Preparation Thereof, Pharmaceutical Compositions Comprising Them, and Therapeutic Uses Thereof | MERCK PATENT GMBH (DE) | 2008-08-14 | — | — | US | disclosed |
| US-20080194608-A1 | 6-Phenylhex-5-Enoic Acid Derivatives, Process for the Preparation Thereof, Pharmaceutical Compositions Comprising Them, and Therapeutic Uses Thereof | MERCK PATENT GMBH (DE) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194608-A1 | 6-Phenylhex-5-Enoic Acid Derivatives, Process for the Preparation Thereof, Pharmaceutical Compositions Comprising Them, and Therapeutic Uses Thereof | PCSK9, HMGCR, LIPA | HRH3 1330/4885CYP1A2 458/4885CYP2D6 43/4885 |
| US-11767317-B1 | Methods of synthesizing enantiopure deuterium-enriched pioglitazone | PPARD, GLP1R, DPP4 | HRH3 2524/4885CYP1A2 421/4885CYP2D6 42/4885 |
| US-20090042872-A1 | Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same | PTPRR, PTPRG, PTPRS | HRH3 2211/4885CYP1A2 3761/4885CYP2D6 3014/4885 |
| US-20210403464-A1 | CRYSTALLINE FORMS OF DEUTERIUM-ENRICHED PIOGLITAZONE | PPARD, PPARA, PPARG | HRH3 2702/4885CYP1A2 1056/4885CYP2D6 406/4885 |
| US-11319313-B2 | Crystalline forms of deuterium-enriched pioglitazone | PPARD, PPARA, PPARG | HRH3 2702/4885CYP1A2 1056/4885CYP2D6 406/4885 |
| US-20090048230-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS | CTSS, CTSZ, CTSF | HRH3 894/4885CYP1A2 2567/4885CYP2D6 1718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.